ERBB2 and non-small cell lung carcinoma: A phase-I study showed good antitumor activity in HER-2 mutant NSCLC and objective response in 72.7% of the patients (n = 11; 95% confidence interval [CI], 39.0 to 94.0), but interstitial lung disease (ILD) emerged as a specific safety signal [76].